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Summary
Background No access to safe water is an important risk factor for typhoid fever, yet risk-level heterogeneity is 
unaccounted for in previous global burden estimates. Since WHO has recommended risk-based use of typhoid 
polysaccharide vaccine, we revisited the burden of typhoid fever in low-income and middle-income countries (LMICs) 
after adjusting for water-related risk.
Methods We estimated the typhoid disease burden from studies done in LMICs based on blood-culture-conﬁ rmed 
incidence rates applied to the 2010 population, after correcting for operational issues related to surveillance, limitations 
of diagnostic tests, and water-related risk. We derived incidence estimates, correction factors, and mortality estimates 
from systematic literature reviews. We did scenario analyses for risk factors, diagnostic sensitivity, and case fatality 
rates, accounting for the uncertainty in these estimates and we compared them with previous disease burden estimates.
Findings The estimated number of typhoid fever cases in LMICs in 2010 after adjusting for water-related risk was 
11·9 million (95% CI 9·9–14·7) cases with 129 000 (75 000–208 000) deaths. By comparison, the estimated risk-
unadjusted burden was 20·6 million (17·5–24·2) cases and 223 000 (131 000–344 000) deaths. Scenario analyses 
indicated that the risk-factor adjustment and updated diagnostic test correction factor derived from systematic 
literature reviews were the drivers of diﬀ erences between the current estimate and past estimates.
Interpretation The risk-adjusted typhoid fever burden estimate was more conservative than previous estimates. 
However, by distinguishing the risk diﬀ erences, it will allow assessment of the eﬀ ect at the population level and will 
facilitate cost-eﬀ ectiveness calculations for risk-based vaccination strategies for future typhoid conjugate vaccine.
Funding Bill and Melinda Gates Foundation.
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Introduction
Access to safe water and sanitation is inadequate in many 
parts of the world. The scarcity of these basic amenities 
weighs heavily on public health, and typhoid fever—a 
severe life-threatening illness caused by Salmonella serovar 
Typhi—is one of the many unfortunate consequences.
Several eﬀ orts have been made to estimate the global 
burden of typhoid fever.1–5 Crump and colleagues2 
estimated 21·6 million cases (range 10·8–43·3 million) in 
the year 2000 with the highest incidence in children in 
south and southeast Asia. Buckle and colleagues3 later 
estimated 13·9–26·9 million cases worldwide for 2010. 
Although, these estimates provide a broad measure of the 
typhoid burden, approaches that distinguish the risk 
diﬀ erences by population groups within countries are 
necessary. WHO’s typhoid position paper6 suggested 
targeting of high-risk populations for polysaccharide 
vaccination.6,7 Therefore, strategies for typhoid conjugate 
vaccination need to appraise the consequences of targeting 
high-risk populations as opposed to universal vaccination.
We aimed to revisit the disease burden of typhoid fever 
in low-income and middle-income countries (LMICs) 
where vaccines would most likely be deployed. Hence, 
we include only LMICs based on World Bank criteria8 
and exclude high-income countries and the European 
region from our analyses. We use updated longitudinal 
surveillance data and a revised estimate of the diagnostic 
sensitivity of blood culture. Additionally, we attempt to 
estimate separate incidence for high-risk populations 
and the rest based on water-related risk. The incidence 
diﬀ erentiation will provide information to assess the 
trade-oﬀ s in terms of health eﬀ ect and cost-eﬀ ectiveness 
of targeted versus universal vaccination strategies for 
typhoid conjugate vaccine.
Methods
We estimated the disease burden from typhoid fever in 
LMICs using adjusted incidences obtained from 
population-based, longitudinal studies (ﬁ gure 1). 
Incidence of typhoid fever in LMICs 
To identify relevant studies, we ﬁ rst did a systematic 
literature review of population-based, longitudinal 
studies of blood-culture-conﬁ rmed typhoid fever (for 
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search strategy see panel). For typhoid vaccine trials, we 
used typhoid incidences from placebo groups only. We 
omitted from this analysis studies from typhoid fever 
outbreaks and hospital-based reports.
We adjusted incidences for the underestimation biases 
resulting from the proportion of patients refusing blood 
draws for culture and the proportion of the population 
who did not use study sentinel sites for health care. For 
the adjustment, we assumed that patients refusing blood 
draws would have the same incidence as those who did 
not, and that the population accessing sentinel health 
facilities would have the same typhoid incidence rate as 
those who did not.
We then adjusted these incidences by age and applied 
them to the total population in the countries in the 
assigned UN region to obtain incidences at a country 
level. The distribution of typhoid fever cases by age group 
was based on studies that presented age-speciﬁ c typhoid 
fever incidence. Data suggest that the average age of 
typhoid infection is lower in areas with high incidence.2,9 
Therefore, we estimated the age-group distribution 
separately for high-incidence populations (>100 cases 
per 100 000 person-years) and medium-incidence 
(10–100 cases per 100 000 person-years) populations.
We classiﬁ ed countries by their respective UN region.10 
And, for every UN region, we calculated the mean 
incidence from the population-weighted average of 
nation-speciﬁ c incidences within the same region. We 
derived country-speciﬁ c estimates after weighting for 
population age distribution (three age groups), proportion 
of population living in urban slums, and population living 
in rural areas without access to improved water. We 
imputed the regional mean incidence estimate for 
countries without typhoid fever incidence estimates. For 
regions without regional incidence rate estimates, we 
assigned values from the average of neighbouring regions.
Adjustment for blood culture sensitivity
Because of the low sensitivity of blood culture, we also 
adjusted incidences for the diagnostic sensitivity of blood 
culture. We estimated the diagnostic sensitivity of blood 
culture on the basis of a second systematic literature 
review to select studies that reported both blood culture 
and bone-marrow culture for the same person (see panel 
for search strategy). Since data suggest that blood culture 
might be positive in the presence of a negative bone-
marrow culture,11–14 we counted people who tested positive 
either by bone marrow or blood culture as true positives 
and, for this analysis, calculated the diagnostic sensitivity 
as the proportion of blood-culture-positives out of all true 
positives. We then estimated the case-weighted average 
of blood-culture sensitivity based on all selected studies.
Adjustment based on risk-factor analysis
Unlike previous burden estimates, we also adjusted the 
typhoid incidence based on water-related risk. Most 
typhoid fever studies are undertaken in populations 
believed to be at increased risk of typhoid fever, often 
urban slums that do not have access to safe water. Data 
from these studies might not be applicable to the whole 
population. To account for this, we used a surrogate 
indicator for safe water, “access to improved water”, as 
deﬁ ned by WHO-UNICEF.15 This variable was selected 
because of the strong linkage between water and typhoid 
transmission and the availability of typhoid risk-factor 
studies that assessed the risk associated with this variable.
To estimate the increased risk of typhoid fever due to 
poor access to safe water, we did a third systematic 
literature review to identify typhoid fever case-control 
studies reporting odds ratio for exposure to improved 
water versus unimproved water (see panel for search 
strategy). If a study identiﬁ ed water source as “improved” 
on the basis of the WHO-UNICEF deﬁ nition but reported 
water source as “microbiologically unsafe” (WHO 
deﬁ nition, >1 colony-forming unit [CFU]/mL Escherichia 
coli), we deemed the water source as “unimproved” to 
represent increased risk. The mean value for pooled odds 
ratio was summarised on the basis of meta-analysis and 
was used in risk-factor correction as a surrogate for 
access to improved water. Two methods were deployed in 
estimating typhoid fever incidence: risk-factor-adjusted 
and risk-factor-unadjusted. The risk-factor-adjusted 
approach classiﬁ es populations into high-risk and at-risk 
categories. We deﬁ ned high risk as a rural population 
lacking access to improved water and an urban 
population living in slums. We deﬁ ned at-risk as a rural 
population having access to improved water and an 
urban population not living in slums. In the ﬁ rst 
approach, for high-risk populations, we directly applied 
age-group-speciﬁ c incidences from longitudinal studies. 
For at-risk populations, we applied age-group-speciﬁ c 
incidences after correcting for the risk-factor—ie, the 
lower risk of infection (ﬁ gure 1). In the second approach, 
where risk factors were not adjusted for, we directly 
applied age-speciﬁ c incidences from longitudinal studies 
to the whole population in the country.
Global population data and case-fatality rates
We extracted population estimates for the year 2010 for 
LMICs from a UN database16 in three age categories 
(0–4·9, 5–14·9, ≥15 years). The fraction of the population 
residing in urban slums and population with poor access 
to improved water sources was extracted from the UN 
Millennium Development Goals Indicators database.17 
For the countries without this information, we used the 
regional population-weighted average estimate.
We estimated the case-fatality rates (CFRs) on the basis 
of an additional literature review and applied this value to 
total typhoid fever cases to calculate the total number of 
typhoid deaths. Typhoid fever CFR is likely to vary with 
access to health-care services. Although the CFR was 
greater than 15% in the pre-antibiotic era,18 a CFR of 
1–4% is widely accepted now.6 A conservative 1% CFR 
was used in previous disease burden estimates,2,3 which 
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we applied as a baseline rate. Published work indicated a 
higher CFR associated with various typhoid outcomes in 
the African region than in other regions.19 Accordingly, 
we considered a lower CFR outside Africa in the 
alternative scenario.
Uncertainty and scenario analyses
The uncertainty associated with every incidence estimate 
from longitudinal studies was accounted for by creating a 
probability distribution for each input variable. We 
applied β-PERT distributions to estimate the blood-
culture sensitivity, risk-factor correction, and CFR 
estimates. We did a Monte Carlo simulation based on 
5000 random draws from each of the input distributions 
to conduct probabilistic multivariate sensitivity analysis 
and to estimate 95% CIs for cases and deaths using 
Ersatz (Version 1.31, Epigear International, Brisbane, 
Australia).20
We estimated the typhoid fever disease burden under 
alternative scenarios for risk-factor, blood-culture 
sensitivity, and CFR outside Africa. The results were 
compared with two previous studies2,3 of the global 
burden of typhoid fever. Since one2 of the studies was 
based on a population from 2000, we extrapolated the 
incidence to a population from 2010 for comparison.
Total population High-risk categories17 High-risk populations
Urban slum
(% of total 
population)
Rural, with no 
access to 
improved water
(% of total 
population)
Fraction
(% of total 
population)
Population size
Africa
East Africa 326 151 000 15% 43% 58% 187 816 425
Middle Africa 128 209 000 30% 38% 68% 87 276 422
North Africa 212 387 000 16% 9% 25% 53 836 931
West Africa 306 044 000 26% 32% 58% 178 129 405
South Africa 57 967 000 17% 8% 25% 14 472 788
Asia
East Asia 1 380 837 000 13% 11% 24% 334 633 289
South Asia 1 719 118 000 12% 11% 23% 398 354 439
Central Asia 61 346 000 1% 12% 13% 8 011 657
Southeast Asia 584 372 000 15% 10% 25% 144 837 488
West Asia 180 898 000 17% 9% 25% 45 610 731
Latin America
Caribbean 44 782 000 29% 11% 40% 17 855 083
Central America 153 118 000 13% 5% 18% 27 219 642
South America 392 985 000 21% 6% 27% 105 339 220
Total 5 557 307 000 15% 14% 29% 1 608 592 886
Table 1: Total population and high-risk populations of po tential typhoid endemic countries
Population-based
typhoid incidence studies
(field sites)
Site-specific incidence
Corrected site-specific incidence
Age group-specific incidence
extrapolated to UN region
Incidence in at-risk population
(country level)
Incidence in high-risk population
(country level)
Risk-factor adjusted overall 
incidence cases (country level)
Risk-factor unadjusted overall 
incidence cases (country level)
Weak
evidence
Risk-factor
correction
Systematic literature review 
for blood culture (BC) sensitivity
Blood-culture
sensitivity correction
Systematic literature review 
for typhoid incidence
No correction
Age group-distribution correction
Study-specific correction
for operational issues
Systematic literature review 
for risk factor related to water
Typhoid deaths (country level) Typhoid deaths (country level)
Literature review for case 
fatality rate
Sensitivity analysis
Figure 1: Flowchart of typhoid disease burden estimation
*We deﬁ ned high risk as “rural population lacking access to improved water and urban population living in slums”. We deﬁ ned at-risk as “rural population having 
access to improved water and urban population not living in slums”.
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Year Incidence by age 
group
Overall 
incidence
North Africa
Sharkia, Egypt21 2001 6 (all age groups) 6
Fayoum, Egypt22 2002 29 (all age groups) 29
Regional ·· 11 (0–4 years);
47 (5–14 years);
10 (≥15 years)
18
West Africa
Ashanti region, 
Ghana23,24
2007–09 196 (0–1 year);
424 (2–4 years);
117 (5–14 years);
NA (≥15 years)
NA
Regional ·· 328 (0–4 years);
117 (5–14 years);
78 (≥15 years)
123
East Africa
Kibera, Kenya25 2007–09 821 (0–1 year);
2243 (2–4 years);
1788 (5–9 years);
870 (10–14 years);
231 (≥15 years)
822
Lwak, Kenya25 2007–09 345 (0–1 years);
742 (2–4 years);
215 (5–9 years);
260 (10–14 years);
608 (≥15 years)
444
Pemba, Zanzibar, 
Tanzania26
2009–10 42 (0–4 years);
51 (5–14 years);
64 (≥15 years)
55
Regional ·· 719 (0–4 years);
662 (5–14 years);
296 (≥15 years)
465
South Africa
Eastern Transvaal, South 
Africa27
1985–88 387 (5–14 years)
Regional ·· 395 (0–4 years);
387 (5–14 years);
111 (≥15 years)
195
East Asia
Quan county, Guangxi, 
China28
1995–96 NA (0–4 years);
14 (5–9 years);
25 (10–14 years);
32 (15–19 years);
13 (≥20 years)
NA
Hechi, Guangxi, China8 2001–02 NA (0–4 years);
29 (5–14 years);
12 (≥15 years)
NA
Regional ·· 57 (0–4 years);
24 (5–14 years);
14 (≥15 years)
18
South Asia
New Delhi, India29 1995–96 1623 (0–1 year);
4170 (2–4 years);
1664 (5–9 years);
1424 (10–14 years);
1026 (15–19 years);
134 (≥20 years)
1166
Kolkata, India9 2003–04 90 (0–1 year);
343 (2–4 years);
498 (5–14 years);
121 (≥15 years)
216
(Table 2 continues in next column)
Year Incidence by age 
group
Overall 
incidence
(Continued from previous column)
Kolkata, India30 2005–06 1233 (2–4 years);
589 (5–14 years);
57 (≥15 years)
NA
Dhaka, Bangladesh31 2000–01 1869 (0–4 years);
209 (≥5 years)
395
Dhaka, Bangladesh32 2003–04 1456 (0–4 years);
120 (≥5 years)
282
Karachi, Pakistan33 1999–01 375 (2–4 years);
945 (5–9 years);
751 (10–14 years);
NA (≥15 years)
NA
Karachi, Pakistan9 2002–04 598 (2–4 years);
431 (5–14 years);
NA (≥15 years)
NA
Periurban Karachi, 
Pakistan34
2007–08 443 (0–1 year);
380 (2–4 years);
NA (5–14 years);
NA (≥15 years)
NA
Karachi, Pakistan35 2002–07 265 (2–4 years);
228 (5–14 years)
NA
Regional ·· 1319 (0–4 years);
773 (5–14 years);
148 (≥15 years)
405
Southeast Asia
Jakarta, Indonesia8,36 2002–03 17 (0–1 year);
283 (2–4 years);
285 (5–9 years);
327 (10–14 years);
327 (15–19 years);
84 (≥20 years)
160
Sumatra, Indonesia37 1986–89 1307 (2–4 years);
1352 (5–9 years);
1150 (10–14 years);
987 (15–19 years)
NA
Dong Thap Province, 
Vietnam38
1995–96 NA (0–4 years);
NA (5–14 years);
NA (≥15 years)
288
Dong Thap Province, 
Vietnam39
1998–00 414 (2–4 years);
NA (5–14 years);
NA (≥15 years)
NA
Hue, Vietnam9 2002–03 25 (5–14 years);
11 (≥15 years)
NA
Regional ·· 619 (0–4 years);
630 (5–14 years);
160 (≥15 years)
282
South America
Santiago, Chile40 1986–89 NA (0–4 years);
83 (5–9 years);
100 (10–14 years);
NA (≥15 years)
NA
Santiago, Chile41 1982–87 NA (0–4 years);
120 (5–14 years);
NA (≥15 years)
NA
Regional ·· 28 (0–4 years);
106 (5–14 years);
15 (≥15 years)
29
NA=not available.
Table 2: Region and site speciﬁ c typhoid fever incidence (per 
100 000 people) from systematic literature review (adjusted for study 
speciﬁ c operational issues; not adjusted for blood-culture sensitivity)
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Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
The endemic population in LMICs was about 5·6 billion 
in 2010 (table 1). The population at high risk of typhoid 
infection was about 1·6 billion (29%) whereas the 
remainder 4·0 billion were at risk.
The ﬁ rst systematic literature review identiﬁ ed 22 papers 
presenting population-based, longitudinal studies of 
incidence estimates for blood-culture-conﬁ rmed typhoid 
fever from 20 distinct sites in LMICs (table 2).9,21–41 
Although studies were published from 1990 to 2013, the 
incidence estimates ranged from 1982 to 2010.
On the basis of four studies in countries with high 
incidence of typhoid fever, the estimated proportion of 
typhoid cases was 21% for the age group of 0–4·9 years, 
40% for that of 5–14·9 years, and 39% for those aged 
15 years or older.9,25,29,36 The corresponding proportion in 
medium-incidence countries was 7% for the age group of 
0–4·9 years, 54% for that of 5·0–14·9 years, and 39% 
those aged 15 years or older, based on three studies.22,26,28
The second systematic literature review identiﬁ ed ten 
papers that presented results of both blood culture and 
bone-marrow culture on the same patient.11–14, 42–47 Of the 
529 patients who tested positive by either blood culture 
or bone marrow culture, 327 (62%) were reported positive 
by blood culture. We estimated a case-weighted average 
diagnostic sensitivity of blood culture of 61·1% (95% CI 
51·9–70·3; table 3).
The third systematic literature review identiﬁ ed 12 case-
control studies48–59 that presented odds of typhoid fever for 
exposure to unimproved water versus improved water 
from ten diﬀ erent countries (panel). Of the 915 cases of 
typhoid fever and 1609 controls, 576 (63%) cases and 
745 (46%) controls were exposed to unimproved water. 
Based on a random-eﬀ ects model that accounted for 
heterogeneity between the studies, the pooled odds of 
exposure to unimproved water was 2·4 (95% CI 1·7–3·6) 
in typhoid fever cases compared with the controls, which 
was used for risk-factor correction (table 3).
The risk-adjusted overall incidence of typhoid fever for 
2010 was 214 per 100 000 individuals and the risk-unadjusted 
overall incidence was 371 per 100 000 individuals, which we 
compared with the incidences reported by Crump and 
colleagues2 extrapolated to the 2010 population (ﬁ gure 2). 
On the basis of risk-factor-corrected and diagnostic 
sensitivity-corrected incidence, 23 Asian countries and 
45 African countries had high incidence of typhoid fever 
(ﬁ gure 3).
Data for the CFRs of typhoid fever from longitudinal 
studies were scarce. We identiﬁ ed two studies: one in our 
review from Ghana23 that reported a CFR of 2·7% and 
another from Nepal60 which had reported a CFR of 1·8% 
in the past.
As a conservative approach, we multiplied estimates of 
CFRs in people with typhoid fever admitted to hospital and 
rate of hospital admission in people with typhoid fever in 
scenario analysis, assuming zero deaths outside hospitals. 
On the basis of a review,61 we estimated a case-weighted 
mean CFR of 2·8% (95% CI 2·0–3·6) using a random-
eﬀ ects model that accounted for heterogeneity between 
the studies. The review had reported 7415 cases of patients 
with typhoid fever admitted to hospital and 259 deaths in 
28 studies from 15 countries during 1984–2005 (appendix). 
We identiﬁ ed weighted mean rates of hospital admission 
of 7·7% (4·3–11·1) from eight studies9,21,22,25,29,31,32,34 presenting 
hospital admission rates in 13 sites in our longitudinal 
incidence review. Finally, we multiplied a randomly 
selected hospitalised CFR estimate (from 28 studies) to a 
randomly selected rate estimate of hospital admission 
(from 13 sites) for 1000 times using a bootstrap method to 
estimate an overall CFR of 0·5% (0·4–0·6) for the 
alternative scenario. Since this is a conservative estimate of 
overall CFR, we took the upper bound of this value (0·6%) 
as the lower bound for CFR (1%) in base-case uncertainty 
analysis. Because more severe typhoid cases tend to be 
admitted to hospital, the CFR in admitted patients is likely 
to overestimate overall typhoid CFR, therefore we used the 
lower bound of 2·0% as the upper bound in base-case 
uncertainty analysis (table 3).
The revisited risk-adjusted estimate of typhoid fever in 
LMICs in 2010 was 11·9 million (95% CI 9·9–14·8) cases 
and 128 775 (75 233–208 146) deaths (table 4). Most cases 
and deaths (72·5%) were projected to occur in Asia, with 
59% in south Asia alone.
The probabilistic multivariate sensitivity analysis 
showed that assumptions on risk-factor correction, blood-
culture sensitivity, and the CFR were the drivers of greatest 
uncertainty, for which we present scenario analyses.
The risk-factor-unadjusted typhoid burden was 
20·6 million cases (95% CI 17·5–24·2) and about 
Mean (95% CI) Estimation method
Odds of exposure to unimproved water in 
typhoid fever cases vs controls48–59*
2·4 (1·7–3·6) Systematic literature review 
and meta-analysis
Percentage of blood-culture sensitivity 
—base case11–14,42–47
61·1% (51·9–70·3) Systematic literature review 
and weighted average
Percentage of blood-culture sensitivity 
—alternate case2,3
50·0% (40·0–60·0) Reference from past studies
Percentage of case-fatality rate in hospitalised 
aptients with typhoid 61
2·87% (2·0–3·6) Weighted average
Percentage of hospital admission rate among 
cases with typhoid fever9,21,22,25,29,31,32,34
7·7% (4·3–11·1) Systematic literature review 
and weighted average
Percentage of overall case-fatality rate: 
Asia and Africa—base case2,3
1·0% (0·6–2·1) Monte-Carlo simulation of 
weighted average
Percentage of overall case fatality rate: 
Asia—alternate case2,3
0·5% (0·4–0·6) Monte-Carlo simulation of 
weighted average
*Used as a surrogate indicator for water related risk of typhoid fever.
Table 3: Assumptions used in base case and sensitivity analysis for estimation of typhoid cases and deaths 
See Online for appendix
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222 000 deaths (95% CI 131 000–344 000; table 5). We 
compared the previous disease burden estimates with 
our estimates, applying 50% blood-culture sensitivity 
and risk-factor correction (mean=25·3 million; 95% CI 
20·9–30·5).
Discussion
Our data suggest that the global burden of typhoid fever 
remains high in LMICs, especially in south Asia. 
Compared with the previous two global burden 
estimates,2,3 both the number of cases and deaths are 
lower in our analysis. However, when we made the same 
assumptions as did these previous approaches, our 
results were similar, with gross overlapping of CIs. This 
similarity shows that our disease burden approach is 
coherent with previous estimates apart from the addition 
of systematic literature-based updates and risk-factor 
adjustments. This ﬁ nding also indicates that global 
disease burden estimates that do not account for risk 
factors might overestimate the disease burden compared 
with studies that account for risk from poor access to 
improved water.
The disease burden method used here has a clear 
advantage over past estimates in evidence-based decision 
making, particularly for WHO policy guidance for typhoid 
conjugate vaccine. WHO has recommended targeting of 
Figure 3: Typhoid incidence in low-income and middle-income countries (risk-adjusted and corrected for blood culture sensitivity)
Study sites
Low (<10 per 100 000 per year)
Middle (10–100 per 100 000 per year)
High(>100 per 100 000 per year)
Typhoid incidence (overall populations)
Figure 2: Typhoid incidence in low-income and middle-income countries using three methods (unadjusted for blood-culture sensitivity)
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high-risk populations with existing polysaccharide 
vaccine for typhoid control,6,7 but has not issued a 
recommendation for typhoid conjugate vaccine. However, 
the proportion of cases of typhoid fever that occur in 
high-risk and at-risk areas has not been well deﬁ ned until 
now. Our study presents diﬀ erential incidence of typhoid 
fever for high-risk versus at-risk populations, which will 
help with the estimation at a population level impact and 
cost-eﬀ ectiveness of targeted vaccination strategies 
compared with vaccination strategies covering whole 
populations. Such analysis will help to make informed 
decision on vaccination strategies for the use of typhoid 
conjugate vaccine. As we assemble our disease burden 
estimates at country level and by target population, the 
All ages, mean (95% CI) 0–4 years, mean (95% CI) 5–14 years, mean (95% CI) ≥15 years, mean (95% CI)
Africa
North Africa
Cases 33 807 (25 809–44 185) 2317 (1773–3021) 18 413 (14 093–24 009) 13 076 (9959–17 179)
Deaths 366 (206–600) 25 (14–41) 200 (113–326) 142 (80–232)
East Africa
Cases 1 749 861 (1 386 537–2 203 996) 450 196 (299 564–658 362) 669 576 (493 574–891 592) 630 089 (413 788–911 776)
Deaths 18 963 (10 780–30 428) 4879 (2483–8536) 7256 (3982–11 949) 6828 (3494–11 960)
West Africa
Cases 489 669 (309 531–729 282) 204 741 (117 920–321 939) 115 256 (45 730–219 951) 169 672 (107 089–253 018)
Deaths 5306 (2660–9271) 2219 (1043–4046) 1249 (452–2687) 1839 (920–3213)
Middle Africa
Cases 713 517 (568 060–887 805) 196 082 (133 870–280 749) 273 784 (203 597–360 950) 243 651 (163 037–347 637)
Deaths 7732 (4420–12 373) 2125 (1105–3654) 2967 (1637–4874) 2640 (1373–4576)
Southern Africa
Cases 103 542 (76 359–140 868) 21 805 (16 084–29 661) 41 784 (30 821–56 838) 39 952 (29 454–54 368)
Deaths 1122 (619–1886) 236 (130–397) 453 (250–761) 433 (239–728)
Area total
Cases 3 090 395 (2 504 427–3 829 277) 875 141 (627 432–1 203 706) 1 118 813 (848 217–1 462 011) 1 096 440 (781 729–1 501 172)
Deaths 33 490 (19 294–53 147) 9484 (5119–15 951) 12 124 (6802–19 712) 11 882 (6454–20 101)
Asia
East Asia
Cases 221 417 (115 678–446 715) 45 797 (23 918–92 402) 40 756 (21 614–69 338) 134 864 (56 191–310 268)
Deaths 2399 (1028–5212) 496 (213–1078) 442 (197–880) 1462 (518–3487)
South Asia
Cases 7 036 692 (5 468 128–9 175 363) 2 416 881 (1 725 304–3 403 270) 2 754 171 (1 978 194–3 804 861) 1 865 640 (1 256 302–2 790 371)
Deaths 76 256 (43 212–125 905) 26 191 (14 199–44 083) 29 847 (16 265–50 263) 20 218 (10 497–36 204)
Central Asia
Cases 184 835 (143 273–243 803) 63 753 (46 220–88 554) 70 085 (51 250–96 085) 50 997 (35 442–75 322)
Deaths 2003 (1130–3335) 691 (379–1160) 760 (418–1287) 553 (293–978)
Southeast Asia
Cases 1 144 236 (938 721–1 432 281) 203 652 (158 079–265 970) 449 100 (361 251–569 225) 491 484 (400 357–621 305)
Deaths 12 400 (7211–20 080) 2207 (1242–3619) 4867 (2799–7909) 5326 (3082–8627)
West Asia
Cases 29 415 (22 513–38 354) 2040 (1567–2645) 16 306 (12 517–21 178) 11 069 (8432–14 538)
Deaths 319 (180–521) 13 (13–36) 177 (100–289) 120 (68–197)
Area total
Cases 8 616 595 (6 886 651–11 161 349) 2 732 123 (2 016 670–3 802 454) 3 330 418 (2 497 938–4 521 940) 2 554 054 (1 882 029–3 636 465)
Deaths 93 377 (53 650–154 591) 29 608 (16 422–49 925) 36 091 (20 137–60 883) 27 678 (15 186–47 848)
Latin America
Cases 176 057 (136 071–229 933) 13 436 (10 389–17 540) 106 585 (82 413–139 142) 56 037 (43 269–73 250)
Deaths 1908 (1085–3128) 146 (83–239) 1155 (657–1893) 607 (345–997)
Overall
Cases 11 883 047 (9 925 551–14 751 214) 3 620 700 (2 823 518–4 777 421) 4 555 816 (3 643 744–5 856 989) 3 706 531 (2 915 024–4 901 677)
Deaths 128 775 (75 233–208 146) 39 237 (22 349–64 597) 49 371 (28 341–80 787) 40 167 (22 671–66 719)
Table 4: Typhoid fever disease burden in low-income and middle-income countries (adjusted for risk-factor and blood-culture sensitivity)
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data can inform national, regional, or global level decision 
makers as well.
We have used a rigorous approach in selecting 
background information and correction factors for disease 
burden estimates. Two researchers did three systematic 
literature reviews using at least two databases with 
consensus-based paper selection. We excluded several 
papers used in a previous disease burden study3 for various 
reasons such as model-based incidence estimation,62 
repeated information from same sites,62–64 older studies 
predating our cutoﬀ  period,60 non-longitudinal design, and 
absence of diagnostic blood-culture.65,66 Unlike past studies, 
we did additional scenario analysis for CFRs. Also, the use 
of probabilistic sensitivity analysis in our study allows for 
better understanding of the uncertainty in typhoid burden 
estimates than with previous studies.
The high-incidence estimate for south Asia is 
consistent with studies of travellers from high-income 
countries.67–70 However, the high incidence ﬁ gures for 
Africa, to which one Kenyan study contributes heavily,25 
need careful interpretation. The south African datapoint 
is decades old, whereas a recent review of community-
acquired bloodstream infections in Africa showed fewer 
than 10% of isolates were S typhi.71 Evidence of typhoid 
fever in Africa has been reported from hospital-based 
studies72,73 and an upsurge of typhoid fever outbreaks has 
been noted in the past decade, as evidenced in Zambia, 
Zimbabwe, Uganda, Malawi, Mozambique, South Africa, 
Democratic Republic of Congo, and Côte d’Ivoire.74 
However, more robust and direct evidence is needed and 
estimates of African incidence might be better elucidated 
from a multicountry burden study currently underway in 
ten countries.
Our study had limitations. One methodological 
limitation is that we corrected for only one typhoid risk 
factor, whereas many other risk factors (eg, poor 
sanitation, food contamination, and urbanisation and 
population density) might aﬀ ect the incidence of typhoid 
fever. A more complex geospatial model might be needed 
to account for other typhoid-related risk factors. Also, the 
risk-factor surrogate, improved water, might not fully 
represent safe water because improved water could 
become contaminated, as occurs during outbreaks. The 
typhoid CFR is calculated for patients who received 
medical care. Our estimated number of typhoid deaths is 
therefore conservative. Since the number of datapoints is 
insuﬃ  cient to test whether the endpoints are consistent 
across time, we applied data from diﬀ erent years to the 
2010 population, assuming that the incidence did not 
change overtime. This assumption is similar to those of 
past studies of typhoid fever global disease burden.2,3
The study design and intensity of typhoid fever 
surveillance across diﬀ erent studies were variable, which 
might have biased our data. In the absence of data, the 
site-speciﬁ c correction assumed similar risk of typhoid 
fever in those refusing and accepting to provide blood for 
culture and in those who visit or do not visit health 
Base case blood-culture 
(61% sensitivity)
Alternate case 
scenario*
(risk-factor 
unadjusted)
Extrapolation Crump 
et al (2004)2 
incidence to 2010 
population*
Buckle et al 
(2013)32†
Risk-factor 
adjusted
Risk-factor 
unadjusted
Cases
Asia 8 616 595 16 099 831 19 798 213 27 070 632 13 869 372
Africa 3 090 395 4 137 260 5 087 653 1 078 579 12 836 934
Others 176 057 321 089 394 848 645 594 242 432
Total 11 883 047 20 558 180 25 280 715 28 794 805 26 948 738
Base case—deaths (1·0% CFR)
Asia 93 377 174 472 214 551 270 706 NA
Africa 33 490 44 835 55 134 10 786 NA
Others 1908 3480 4279 6456 NA
Total 128 775 222 787 273 964 287 948 269 487
Scenario analysis—deaths (0·5% CFR in Asia and other regions)
Asia 42 236 78 917 NA NA NA
Africa 33 490 44 835 NA NA NA
Others 863 1574 NA NA NA
Total 76 589 125 326 NA NA NA
CFR=case-fatality rate. NA=not available. *Estimations assumed 50% blood-culture sensitivity. †Regional classiﬁ cation 
are slightly diﬀ erent from other estimates; Africa includes middle east; other regions include all regions apart from Asia 
and Africa including developed countries; number of deaths was calculated on the basis of a 1% CFR. 
Table 5: Scenario analysis for typhoid fever disease burden based on correction factors
Panel: Research in context
Systematic review
We did three systematic literature reviews using PubMed and Embase data bases as well 
WHO and Pan American Health Organisation (PAHO) publication databanks. For the 
population-based, longitudinal studies of blood-culture conﬁ rmed typhoid fever review, 
we used the key words (“typhoid” OR “typhoid fever” OR “Salmonella Typhi” OR “S. Typhi” 
OR “salmonella infection” OR “enteric fever”) AND (“incidence” OR “rate” OR “frequency” 
OR “prevalence” OR “morbidity” OR “burden” OR “surveillance” OR “epidemiology”). For 
the sensitivity sensitivity of blood culture in typhoid fever conﬁ rmation review, we used 
the key terms (“typhoid” OR “typhoid fever” OR “Salmonella Typhi” OR “S. Typhi” OR 
“salmonella infection” OR “enteric fever”) AND (“blood” OR “blood culture” OR “culture of 
blood” OR “diagnostics” OR “sensitivity” OR “positivity”). For the increased risk of typhoid 
fever due to lack of access to improved water review, we used the key terms (“typhoid” OR 
“typhoid fever” OR “Salmonella Typhi” OR “S. Typhi” OR “salmonella infection” OR “enteric 
fever”) AND (“risk factors” OR “predictive factors” OR “associated factors” OR “attributed 
factors” OR “exposure factors” OR “related factors” OR “predisposing factors”). Except for 
the sensitivity of blood culture in typhoid fever conﬁ rmation review, searches were 
restricted to publications from 1990–2013. All searches were limited to English language 
and studies of human individuals.
Interpretation
On the basis of systematic literature reviews, we synthesised typhoid fever disease burden 
in LMICs. After the recent licensure of a typhoid conjugate vaccine in India, disease burden 
estimates in high-risk populations that might be targeted for vaccination are globally 
needed. This analysis provides the ﬁ rst set of incidence estimates diﬀ erentiated by 
risk-population, age, country, and region. The approach can help in the assessment of 
age-targeted and risk-targeted strategies for typhoid conjugate vaccination to support 
policy and ﬁ nancing decisions.
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facilities. We could not account for previous antibiotic 
use and volume of blood taken, which are known to aﬀ ect 
blood-culture sensitivity. Also, fever surveillance studies 
might have underestimated typhoid fever incidence in 
children younger than 2 years because of atypical 
presentations and diﬃ  culty in drawing blood for culture. 
Similarly, we could not measure bias because of the strict 
inclusion criteria of placebo groups in clinical trials.
The data for Latin American and the Caribbean are 
limited to two clinical trials40,41 done more than 20 years 
ago, and this might have overestimated the typhoid 
burden due to improved water and sanitation in recent 
years. On the other hand, we might have underestimated 
the incidence from older data because increasing 
urbanisation and population density in recent years 
might have increased risk of typhoid fever. Latin America 
and parts of Asia and Africa are poorly represented in 
this review and hence typhoid fever surveillance in these 
locations is necessary for better understanding of current 
disease burden. Finally, our review does not include 
publications that are not in English. However, we believe 
this limitation will have minimal implications for our 
ﬁ ndings since the previous systematic literature review3 
searching for papers in Spanish, Italian, French, and 
Portuguese did not ﬁ nd any published work on typhoid 
fever incidence from 1980 to 2009.
In conclusion, this revised global typhoid burden study 
estimated a lower number of typhoid fever cases and 
deaths than the most recently published estimates, 
particularly because of the use of more conservative 
methods resulting from adjustment for a water-related risk 
factor and updated diagnostic sensitivity of blood culture. 
The burden of typhoid fever continues to be high in Asia; 
and published data from Africa suggest a greater burden 
than previously thought. The results from this analysis are 
useful in informing policies of typhoid vaccination and 
developing guidance on eﬀ ective control measures.
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